tbuckley/cabot-search huggingface dataset:
Pembrolizumab and radiotherapy for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with contraindication to cisplatin therapy
Authors: S. Sheth, J.R. Bauman, A. Deal, B. Chera, C. Shen, T. Galloway, T. Hackman, J. Blumberg, W. Yarbrough, M. Weissler, C. Hilliard, R. Mehra, J. Grilley-Olson, J. Weiss
Journal: Annals of Oncology (2019)
Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma
Authors: E.A. Rozeman, R. Moritz, S. Wilgenhof, J.V. van Thienen, J B A G Haanen, M. van den Heuvel, C.U. Blank, H. Van Rossum
Journal: Annals of Oncology (2019)
Association Between Maternal Exposure to Lead, Maternal Folate Status, and Intergenerational Risk of Childhood Overweight and Obesity
Authors: Guoying Wang, Jessica DiBari, Eric Bind, Andrew M. Steffens, Jhindan Mukherjee, Romuladus E. Azuine, Gopal K. Singh, Xiumei Hong, Yuelong Ji, Hongkai Ji, Colleen Pearson, Barry S. Zuckerman, Tina L. Cheng, Xiaobin Wang
Journal: JAMA Network Open (2019)

<h3>Importance</h3> The first pediatric lead screening typically occurs at 1-year well-child care visits. However, data on the extent of maternal lead exposure and its long-term consequences for child health are lacking. <h3>Objective</h3> To investigate the associations between maternal red blood cell (RBC) lead levels and intergenerational risk of overweight or obesity (OWO) and whether adequate maternal folate status is associated with a reduction in OWO risk. <h3>Design, Setting, and Participants</h3> Prospective birth cohort study. The analysis was conducted from July 14, 2018, to August 2, 2019, at Johns Hopkins Bloomberg School of Public Health. This study included 1442 mother-child pairs recruited at birth from October 27, 2002, to October 10, 2013, and followed up prospectively at Boston Medical Center. <h3>Main Outcomes and Measures</h3> Child body mass index (BMI)<i>z</i>score, calculated according to US national reference data, and OWO, defined as BMI at or exceeding the 85th percentile for age and sex. Maternal RBC lead levels and plasma folate levels were measured in samples obtained 24 to 72 hours after delivery; child whole-blood lead level was obtained from the first pediatric lead screening. <h3>Results</h3> The mean (SD) age of mothers and children was 28.6 (6.5) years and 8.1 (3.1) years, respectively; 50.1% of children were boys. The median maternal RBC lead level and plasma folate level were 2.5 (interquartile range [IQR], 1.7-3.8) μg/dL and 32.2 (IQR, 22.1-44.4) nmol/L, respectively. The median child whole-blood lead level and child BMI<i>z</i>score were 1.4 (IQR, 1.4-2.0) μg/dL and 0.78 (IQR, −0.08 to 1.71), respectively. Maternal RBC lead level was associated with child OWO risk in a dose-response fashion, with an odds ratio (OR) of 1.65 (95% CI, 1.18-2.32) for high maternal RBC lead level (≥5.0 μg/dL) compared with low maternal RBC lead level (&lt;2.0 μg/dL). Child OWO was highest among children of OWO mothers with high RBC lead levels (adjusted OR, 4.24; 95% CI, 2.64-6.82) compared with children of non-OWO mothers with low RBC lead levels. Children of OWO mothers with high RBC lead levels had 41% lower OWO risk (OR, 0.59; 95% CI, 0.36-0.95;<i>P</i> = .03) if their mothers had adequate plasma folate levels (≥20.4 nmol/L) compared with their counterparts. <h3>Conclusions and Relevance</h3> In this sample of a US urban population, findings suggest that maternal elevated lead exposure was associated with increased risk of intergenerational OWO independent of postnatal blood lead levels. Adequate maternal folate status appeared to be associated with lower OWO risk. If confirmed by additional studies, these findings have implications for prenatal lead screening and management to minimize adverse health consequences on children.
EMERGE: Epigenetic modulation of the immune response in gastrointestinal cancers
Authors: E. Cartwright, F. Turkes, C. Saffery, E. Kalaitzaki, R. Powell, A. Wotherspoon, K. De Paepe, K. von Loga, M. Hubank, S. Rao, D. Watkins, I. Chau, N. Starling, D. Cunningham
Journal: Annals of Oncology (2019)
Abstract 834: Residues Leu261, Trp264 and Phe265 Account for Apolipoprotein E Induced Dyslipidemia and Affect the Biogenesis of Apolipoprotein E Containing High Density Lipoprotein
Authors: Konstantinos Drosatos, Kyriakos E Kypreos, Vassilis I Zannis
Journal: Circulation (2006)
Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): The phase III ATTRACTION-3 study
Authors: B.C. Cho, K. Kato, M. Takahashi, M. Okada, C.-Y. Lin, K. Chin, S. Kadowaki, M.-J. Ahn, Y. Hamamoto, Y. Doki, C.-C. Yen, Y. Kubota, S.-B. Kim, C.-H. Hsu, E. Holtved, I. Xynos, M. Kodani, Y. Kitagawa
Journal: Annals of Oncology (2019)
An expert panel consensus on opioid-prescribing guidelines for dermatologic procedures
Authors: Justin M. McLawhorn, Matthew P. Stephany, William E. Bruhn, Lauren D. Crow, Brett M. Coldiron, George J. Hruza, Brian C. Leach, Seaver L. Soon, Daniel P. Friedmann, William G. Stebbins, Travis W. Blalock, Michael S. Graves, Elizabeth M. Billingsley, Thomas J. Knackstedt, Stanley J. Miller, Edward H. Yob, John G. Albertini, Nathalie Zeitouni, Richard A. Krathen, Christopher K. Bichakjian, Nathaniel J. Jellinek, C. William Hanke, Faramarz H. Samie, Margaret W. Mann, John A. Carucci, Rohit Kakar, Drew K. Saylor, Scott W. Fosko, Arisa E. Ortiz, William B. Henghold, Thomas A. Jennings, DiAnne S. Davis, Mary E. Maloney, Natalie M. Curcio, Ramona Behshad, Whitney D. Tope, Holly McCoppin, Jarad I. Levin, Lindsey Collins, Thomas Stasko
Journal: Journal of the American Academy of Dermatology (2019)
IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib plus nivolumab in advanced soft tissue and bone sarcomas: Results of the phase II- soft-tissue sarcoma cohort
Authors: J Martin Broto, N. Hindi, G.E. Grignani, J Martinez Trufero, A. Redondo, C. Valverde, A Lopez Pousa, S. Stacchiotti, E. Palmerini, E. de Alava, D.S. Moura, H Perez Vega, P. Collini, I. Otero, P. Ledesma, E. Marchesi, L. D’Ambrosio, J A Lopez Martin
Journal: Annals of Oncology (2019)
A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
Authors: K. Fizazi, A. Maillard, N. Penel, G. Baciarello, D. Allouache, G. Daugaard, A. Van de Wouw, G. Soler, E. Vauleon, L. Chaigneau, R. Janssen, F. Losa Gaspa, R. Morales Barrera, C. Balana, D. Tosi, B. Chauffert, C.A. Schnabel, G. Martineau, S. Culine, I. Borget
Journal: Annals of Oncology (2019)
Efficacy and safety of dabrafenib and trametinib in patients with metastatic BRAFV600 mutation-positive melanoma in the real-world setting: Interim results of the non-interventional COMBI-r study
Authors: C. Berking, E. Livingstone, M. Weichenthal, U. Leiter, K. Wittmann, T. Eigentler, P. Mohr, F. Kiecker, C. Loquai, D. Debus, R. Gutzmer
Journal: Annals of Oncology (2019)
High-Level Setd8 Expression Is Important for Establishment of Normal Patterns of Erythroid Gene Expression and Is Essential for Stress Erythropoiesis
Authors: Tyler A Couch, Zachary C. Murphy, Jacquelyn Lillis, Michael Getman, Paul D. Kingsley, Ryo Kurita, Yukio Nakamura, Laurie A. Steiner
Journal: Blood (2018)
A phase I study of intraperitoneal MCY-M11 Anti-mesothelin CAR for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy
Authors: C. Annunziata, C. Dansky-Ullmann, A. Ghobadi, D. Weng, J. Vanas, I. Ekwede, M. Pavelova, R. Keefe, M. Kuo, R. Hassan, P. Thaker
Journal: Annals of Oncology (2019)
Estimated Association Between Organ Availability and Presumed Consent in Solid Organ Transplant
Authors: Luke J. DeRoos, Wesley J. Marrero, Elliot B. Tapper, Christopher J. Sonnenday, Mariel S. Lavieri, David W. Hutton, Neehar D. Parikh
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Presumed consent, or an opt-out organ transplant policy, has been adopted by many countries worldwide to increase organ donation. The implication of such a policy for transplants in the United States is uncertain, however. <h3>Objective</h3> To simulate the potential implications of a presumed consent policy in the United States. <h3>Design, Setting, and Participants</h3> In a decision analytical model, a simulation model was developed using cohort data from January 1, 2004, to December 31, 2014, in the Organ Procurement and Transplantation Network Standard Transplant Analysis and Research files. All US patients (n = 524 359) who were on the waiting list for at least 1 solid organ and all deceased organ donors during the study period were included in the analyses. All data and statistical analyses were performed from January 30, 2019, to July 31, 2019. <h3>Main Outcomes and Measures</h3> Increase in the organs available for donation and life-years gained associated with a 5%, 15%, or 25% increase in deceased donors, based on the published changes from a presumed consent policy. <h3>Results</h3> This study considered 524 359 unique candidates (aged ≥18 years; 320 908 [61.2%] male) for a solid organ transplant from January 1, 2004, to December 31, 2014. With a base case scenario of a 5% presumed consent–associated increase in donors, the removals (owing to death or illness) from the waiting list for all organs would have an associated 3.2% to 10.4% mean reduction, depending on the random or ideal allocation of new organs to patients on the waiting list. Sensitivity analyses showed that waiting list removals could be decreased up to 52%; however, this reduction was not enough to completely eliminate waiting list removals during the study period. The biggest estimated increases in annual life-years gained associated with a presumed consent policy were in kidney transplant candidates (95% CIs by deceased donor increase: 5% increase, 3440-3466 years; 15% increase, 10 321-10 399 years; 25% increase, 17 201-17 332 years) and liver transplant candidates (95% CIs by deceased donor increase: 5% increase, 898-905 years; 15% increase, 2693-2714 years; 25% increase, 4448-4523 years). Adoption of a presumed consent policy could result in a 4295-year (95% CI, 4277-4313 years) to 11 387-year (95% CI, 11 339-11 435 years) increase in life-years, accounting for the survival advantages associated with a transplant. <h3>Conclusions and Relevance</h3> In this study, presumed consent was estimated to be associated with modest but important improvement in the number of organ transplants and increases in life-years gained for patients awaiting an organ transplant. Further consideration and even debate about the ethical and public policy implications of a presumed consent policy are warranted.
Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy
Authors: L. Nappi, M. Thi, B.J. Eigl, K.N. Chi, M.E. Gleave, A. So, P.C. Black, R. Hamilton, S. Daneshmand, C.R. Nichols, C.K. Kollmannsberger
Journal: Annals of Oncology (2019)
Quality of life during 1st-line FOLFOXIRI+/- panitumumab in RAS wild-type metastatic colorectal cancer: Results from the randomized VOLFI trial (AIO KRK-0109)
Authors: M. Geissler, T. Klingler, D. Modest, J Riera Knorrenschild, T.J. Ettrich, S. Kanzler, V. Heinemann, S. Held, U.M. Martens
Journal: Annals of Oncology (2019)
Randomized controlled trial of percutaneous transesophageal gastrotubing for symptom palliation in patients with malignant gastrointestinal obstruction.
Authors: Miyuki Sone, Takeshi Aramaki, Yasuaki Arai, Shusuke Sugawara, Shinichi Morita, Hiroaki Ishii, Daisuke Okamoto, Yoshito Takeuchi, Michihisa Moriguchi, Emima Bekku, Rui Sato
Journal: Journal of Clinical Oncology (2018)

10090 Background: Malignant gastrointestinal obstruction occurs in approximately 10-16% of end-stage cancer patients. Nasogastric tubing (NGT) is a standard palliative treatment; however, NGT causes nasopharyngeal discomfort, pain, skin ulcer, and difficulties in the appearance care such as shaving or makeup. Percutaneous transesophageal gastrotubing (PTEG) was developed as an image-guided, minimally invasive tube placement directly accessing to the cervical esophagus under local anesthesia. As the previous phase II study of PTEG (JIVROSG-0205) demonstrated high technical success (100%) and clinical efficacy (91%), we hypothesized that patients receiving PTEG would have higher quality of life (QOL) than NGT. The aim of this multicenter, open-label, randomized controlled trial (JIVROSG-0805) was to evaluate the efficacy of PTEG. Methods: Patients with symptomatic malignant gastrointestinal obstruction were randomly assigned (1:1) to receive PTEG or NGT. The primary endpoint was symptomatic scores of four elements (nasopharyngeal discomfort, satisfaction with appearance, restriction of daily life, and sleep disturbance) evaluated with area under the curve (AUC) during 2 weeks after the treatments. Secondary endpoints included change in global health-related QOL (EQ-5D, SF-8) and incidence of adverse events evaluated with CTCAE v.3.0. Results: From October 2009 to January 2015, 40 patients were enrolled (PTEG: 20; NGT: 20). Symptomatic scores were evaluable in 39 patients (PTEG: 19; NGT: 20) and the safety was evaluable in all patients. The AUC of the symptomatic scores of the PTEG group (mean: 149.6; 90% CI: 125.2, 173.9) was significantly higher than that of NGT group (mean: 44.9; 90% CI: 21.2, 68.7) (p< 0.0001). Differences in EQ-5D (mean: 3.5; 90% CI: 1.6, 5.3; p< 0.036) and SF-8 (mean: 220.7; 90% CI: 113.3, 328.1; p< 0.0020) between two groups were statistically significant. There was no procedure-related complication in both groups. Conclusions: This analysis demonstrated the statistical superiority of the PTEG compared to the NGT. PTEG was effective in reduction of the distressing symptoms caused by NGT. Clinical trial information: UMIN000003565.
Impact of clonality and DNA repair mutations on plasma tumour mutation burden (pTMB) and immunotherapy efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) in CCTG CO.26
Authors: J.M. Loree, D.J. Jonker, H. Feilotter, H.F. Kennecke, P.Z. Brohawn, K. Banks, K. Quinn, D. Tu, C. O’Callaghan, E.X. Chen
Journal: Annals of Oncology (2019)
The mutant neoantigen specific T cell is a personalized immunotherapy in refractory solid tumour
Authors: Q. Song, T. Zhang, J. Li, W. Sheng, J. Wang, Q. Gan, L. Han, Q. Sun, N. Zhou, X. Zhou, Y. Zhou, L. Wu, J. LI, L. Chang, Z. Zhou, Y. Song, L. Zhang, S. Jiao
Journal: Annals of Oncology (2019)
Neoadjuvant chemoradiotherapy with/without lateral lymph node dissection for low rectal cancer: Which patients can benefit?
Authors: D. Nishizaki, K. Hida, A. Sumii, Y. Sakai, T. Konishi, T. Akagi, T. Yamaguchi, T. Akiyoshi, M. Fukuda, S. Yamamoto, S. Maruyama, M. Okajima, Y. Miyakura, R. Okamura, S. Arizono, M. Yamamoto, K. Kawada, S. Morita, M. Watanabe
Journal: Annals of Oncology (2019)
Time Given to Trainees to Attempt Cannulation During Endoscopic Retrograde Cholangiopancreatography Varies by Training Program and Is Not Associated With Competence
Authors: Anna Duloy, Rajesh Keswani, Matt Hall, Andrew Y. Wang, Gregory A. Cote, Eva M. Aagaard, Linda Carlin, Christopher J. DiMaio, Steven Edmundowicz, Swan Ellert, Samuel Han, Sri Komanduri, Raman Muthusamy, Amit Rastogi, Raj J. Shah, Violette Simon, Sachin Wani
Journal: Clinical Gastroenterology and Hepatology (2019)
Procedure Mix—The Path to Pay Equity
Authors: Lindsay E. Kuo, Rachel R. Kelz
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Abstract 3502: Chemoproteomics provide insights into cell surface reprogramming during KRAS-mediated transformation
Authors: Neethi Nandagopal, Léo Aubert, Sami Nourreddine, Geneviève Lavoie, Philippe Roux
Journal: Cancer Research (2018)

Abstract KRAS is among the most frequently mutated genes driving human cancers, including ~45% of colorectal cancers (CRC). Despite decades of research, mutant KRAS is considered undruggable, and is frequently associated with resistance to chemotherapy and other targeted therapies. While the effect of mutant KRAS on regulating intracellular signaling events is well studied, much less is known about its impact on the cell surface proteome (surfaceome), which constitutes the predominant therapeutic target for FDA-approved drugs. To study the cell surfaceome, we optimized a chemoproteomics approach that selectively isolates cell surface proteins and allows their relative quantification using mass spectrometry. When comparing normal intestinal cells to their counterparts expressing oncogenic KRAS (G12V), we identified 104 (~13%) and 170 (~22%) cell surface proteins that were significantly upregulated or downregulated, respectively, in KRAS-transformed cells. Overall, a myriad of proteins, including receptors, solute carriers, adhesion molecules, etc., were modulated by mutant KRAS, and their potential roles in KRAS-mediated transformation are currently being studied. We also found that most of the cell surface proteins were altered in response to transcriptional changes induced by KRAS signaling, and due to increased global endocytosis in KRAS-mutated cells. Our study suggests potential cell surface proteins that could be targeted in KRAS-mutant cells, which will be verified in subsequent studies using human CRC models. Our work helps assemble a global view of how oncogenic KRAS alters the spatial distribution of several cell surface proteins, and thereby potentially impacts tumor functions and therapeutic response. Citation Format: Neethi Nandagopal, Léo Aubert, Sami Nourreddine, Geneviève Lavoie, Philippe Roux. Chemoproteomics provide insights into cell surface reprogramming during KRAS-mediated transformation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3502.
NTRK1-3 genomic fusions in non-small cell lung cancer (NSCLC) determined by comprehensive genomic profiling
Authors: S-H I Ou, E.S. Sokol, S.E. Trabucco, D.X. Jin, G.M. Frampton, S.L. Graziano, J.A. Elvin, J.-A. Vergilio, J.K. Killian, N. Ngo, D. Lin, S. Ramkissoon, E. Severson, S.M. Ali, A.B. Schrock, J. Chung, P. Reddy, K. McGregor, B.M. Alexander, J.S. Ross
Journal: Annals of Oncology (2019)
RETRACTED: lncRNA RMST Enhances DNMT3 Expression through Interaction with HuR
Authors: Wan-Xin Peng, Pratirodh Koirala, Wei Zhang, Chao Ni, Zheng Wang, Liu Yang, Yin-Yuan Mo
Journal: Molecular Therapy (2019)

This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been retracted at the request of the editors and the corresponding author (Yin-Yuan Mo). Concerns regarding potentially duplicated western blots in Figures 2I and 3I were raised by readers on PubPeer (https://pubpeer.com/publications/64075911BAD21941D78C27FD3B8DB3#16), and the authors contacted the editorial office with the original blots to issue a correction. Following the correction of the article, the authors provided additional raw data to address further concerns raised by a reader. Given multiple inconsistencies in file labeling and post-acquisition processing, the editors have lost faith in the findings presented in the article. The retraction notice email was undeliverable to the following authors: Chao Ni, Pratirodh Koirala, Wei Zhang, and Wan-Xin Peng.
Studies in Myasthenia Gravis
Authors: Kermit E. Osserman, Lee Burnett Weiner
Journal: New England Journal of Medicine (1965)

IN an earlier paper, a 30 per cent incidence (77 of 256) of positive staining of striated muscle with the serums of patients with myasthenia gravis was reported.1 An indirect immunofluorescent technic employing a rabbit antihuman 7-S gamma globulin was used. It was observed that of 9 patients whose serums showed positive immunofluorescence before thymectomy, 7 changed to negative after surgery. These changes suggested that positive immunofluorescence, when present, may not be a permanent characteristic finding in the disease.Selected patients were studied in an attempt to establish whether antibody immunofluorescence was a reversible phenomenon that could change not only . . .
PERIATRIAL FAT QUALITY PREDICTS ATRIAL FIBRILLATION ABLATION OUTCOME
Authors: Luisa Ciuffo, Hieu Nguyen, Mateus Diniz Marques, Konstantinos Aronis, Henrique Vasconcellos, Bhradeev Sivasambu, Susumu Tao, David D. Spragg, Joseph Edward Marine, Ronald David Berger, Joao A.C. Lima, Hugh Calkins, Hiroshi Ashikaga
Journal: Journal of the American College of Cardiology (2019)
Prior exposure to pazopanib (PAZ) did not minor efficacy of regorafenib (REG) in non-adipocytic soft tissue sarcoma patients (pts)
Authors: N. Penel, J.-Y. Blay, J. Wallet, O. Mir, A. Italiano, F. Bertucci, S. Piperno-Neumann, T. Brodowicz, E. Bompas, B. Liegl-Atzwanger, C.M. Chevreau, I.L. Ray-Coquard, S. Taieb, E. Decoupigny, M C Le Deley, A. Le Cesne
Journal: Annals of Oncology (2019)
Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: Association with toxicity and treatment outcome
Authors: A. Desnoyer, A. Larive, D. Drubay, E. Lanoy, Y. Vano, N. Rioux-Leclercq, S. Chouaib, B. Beuselinck, F. Tantot, B. Escudier, N. Chaput, L. Albiges
Journal: Annals of Oncology (2019)
Perforations oesophagiennes après dilatation instrumentale dans les sténoses caustiques: à propos de 13 cas
Authors: N Oumnia, M Lahcene, A Tebaibia, N Matougui, MA Boudjella, B Touchene
Journal: Endoscopy (2011)

Introduction: Le risque majeur de la dilatation instrumentale est la perforation. Cette complication peut mettre en jeu le pronostic vital surtout en cas de retard diagnostique. L'objectif de notre travail est d'analyser à travers notre expérience, les caractéristiques cliniques et évolutives des perforations au cours de la dilatation des sténoses caustiques oesophagiennes.
A Prediction Model to Help with Oncologic Mediastinal Evaluation for Radiation: HOMER
Authors: Gabriela Martinez-Zayas, Francisco A. Almeida, Michael J. Simoff, Lonny Yarmus, Sofia Molina, Benjamin Young, David Feller-Kopman, Ala-Eddin S. Sagar, Thomas Gildea, Labib G. Debiane, Horiana B. Grosu, Roberto F. Casal, Muhammad H. Arain, George A. Eapen, Carlos A. Jimenez, Laila Z. Noor, Shiva Baghaie, Juhee Song, Liang Li, David E. Ost
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

This prediction model can estimate the probability of N0, N1, and N2|3 disease in patients with NSCLC. The model has the potential to facilitate decision-making in patients with NSCLC when stereotactic ablative radiotherapy is an option.
Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy
Authors: G. Kramer-Marek, J. Maczynska, F. Raes, K. Malarz, C. Da Pieve, M. de Mezer, M. Niedbala, K.J. Harrington, W. Kaspera
Journal: Annals of Oncology (2019)